Low serum irisin levels in newly diagnosed patients with type 2 diabetes mellitus: a meta-analysis

Abstract

Background: Low irisin levels, a marker widely reported to be associated with developing insulin resistance and type 2 diabetes mellitus. This study aims to provide evidence regarding irisin levels in patients newly diagnosed with type 2 diabetes mellitus. Methods: A systematic review and meta-analysis of observational studies in adults over 18 newly diagnosed with type 2 diabetes mellitus. The databases used for this study were PubMed, ProQuest and ScienceDirect. Only English studies were considered in the database searched from the beginning to October 2022. The data obtained were analyzed using the RevMan 5.4 application. Results: Twelve studies met the inclusion criteria. These were identified using a total of 1,621 patients with; 880 cases and 741 controls. This main point shows that the serum irisin level in patients newly diagnosed with type 2 diabetes mellitus has a mean difference of -7.72 with 95% CI -9.49 to -5.95. Since the evidence collected in our meta-analysis showed heterogeneity (I2 = 99%), a random effects model was performed. The z-test results for the overall effect were statistically significant (P≤0.001). Conclusion: Irisin levels were significantly lower in patients newly diagnosed with type 2 diabetes mellitus than in the healthy group.